Professor Jacob George

Professor Jacob George is Professor of Cardiovascular Medicine & Therapeutics at the University of Dundee Medical School. Professionally, he is a Consultant Physician in qualified in Clinical Pharmacology and General Internal Medicine and is an accredited European Hypertension Specialist.  He is a Fellow of the Royal College of Physicians Edinburgh, European Society of Cardiology and the British Hypertension Society. His clinical interest is in managing patients with high Cardiovascular risk and he is Clinical Lead for the Cardiovascular Risk Service in NHS Tayside. His research interests are focused on managing cardiovascular risk factors such as left ventricular hypertrophy, salt and smoking/vaping. His research publications have been covered by more than 50 news organizations worldwide and he has conducted more than 80 media interviews including live television broadcasts to national and international media on the results of his research.

He is actively involved in Medicines Governance in the UK being the Chair of the Scottish Government Access to New Medicines, Horizon Scanning Advisory Board (HSAB), National Clinical Lead for the Scottish Medicines Consortium. He sits on the Steering Group of the Innovative Licensing and Access Pathway (ILAP), a joint initiative between the MHRA, NICE,SMC and AWTTC. Locally, he is Chair of the Medicines Advisory Group and is a member of the PACS Tier 2 Committee. He also sits on the National Review Panel for drugs not approved by the SMC. He was recently appointed by the Minister of Health, Malaysia as an International Expert Advisory Member of the Malaysian Scientific Review Panel for Phase I Clinical Trials.

Professor George is the immediate past chairman of Scottish Heart and Arterial Risk Prevention (SHARP) Society

Dr Jacob George’s Publications

1. Farrell, C., Hannan, F., George, J., et al Effect of vitamin D analogue therapy in a patient with autosomal dominant hypocalcaemia type 2 (ADH2) due to GNA11 p.Arg60Leu mutation. 13 Nov 2019, Endocrine  65, P86. (Case Report)
2. Abo-Leyah H, Gallant S, Cassidy D et al. The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. ERJ Open Res 2021 (DOI: 10.1183/23120541.00080-2021)
3. Al-Talabany S, Mohan M, Weir-McCall J et al. Effect of Metformin on Epicardial Adipose Tissue in Patients With Coronary Artery Disease Without Diabetes: A Cardiac MRI Sub-study of The MET-REMODEL Trial. Obesity Medicine May 2021
4. Curran FM, Bhalraam U, Mohan M et al. Neutrophil to Lymphocyte Ratio and Outcomes in Patients with New-Onset or Worsening Heart Failure with Reduced and Preserved Ejection Fraction. ESC Heart Failure May 2021
5. Witham MD, Achison M,Aspray TJ et al. Recruitment strategies for sarcopenia trials – lessons from the LACE randomised controlled trial. J Cachexia Sarcopenia & Muscle (JCSM) -Rapid Communications. Mar 2021
6. Chungath RC, Witham MD, Clarke CL et al. Association between mitochondrial function measured by 31P Magnetic Resonance Spectroscopy and Physical Performance in older people with functional impairment. J Cachexia Sarcopenia & Muscle (JCSM) July 2021; 6(3):71-79